BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 34725930)

  • 21. The combination of pretreatment prognostic nutritional index and neuron-specific enolase enhances prognosis predicting value of small cell lung cancer.
    Wang C; Jin S; Xu S; Cao S
    Clin Respir J; 2021 Mar; 15(3):264-271. PubMed ID: 33058444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
    Shao N; Cai Q
    Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Higher pretreatment lactate dehydrogenase concentration predicts worse overall survival in patients with lung cancer.
    Deng T; Zhang J; Meng Y; Zhou Y; Li W
    Medicine (Baltimore); 2018 Sep; 97(38):e12524. PubMed ID: 30235773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lactate dehydrogenase and body mass index are prognostic factors in patients with recurrent small cell lung cancer receiving amrubicin.
    Inomata M; Hayashi R; Tokui K; Taka C; Okazawa S; Kambara K; Ichikawa T; Yamada T; Miwa T; Kashii T; Matsui S; Tobe K
    Tumori; 2016 Dec; 102(6):606-609. PubMed ID: 26429641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment serum lactate dehydrogenase as additional staging parameter in patients with small-cell lung carcinoma.
    Stokkel MP; van Eck-Smit BL; Zwinderman AH; Willems LN; Pauwels EK
    J Cancer Res Clin Oncol; 1998; 124(3-4):215-9. PubMed ID: 9619749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combining
    Lin X; Xiao Z; Hu Y; Zhang X; Fan W
    Front Pharmacol; 2020; 11():592768. PubMed ID: 33192532
    [No Abstract]   [Full Text] [Related]  

  • 27. Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes.
    Lee DS; Park KR; Kim SJ; Chung MJ; Lee YH; Chang JH; Kang JH; Hong SH; Kim MS; Kim YS
    Tumour Biol; 2016 Jan; 37(1):619-25. PubMed ID: 26240025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy.
    Quoix E; Purohit A; Faller-Beau M; Moreau L; Oster JP; Pauli G
    Lung Cancer; 2000 Nov; 30(2):127-34. PubMed ID: 11086206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer.
    Sagman U; Feld R; Evans WK; Warr D; Shepherd FA; Payne D; Pringle J; Yeoh J; DeBoer G; Malkin A
    J Clin Oncol; 1991 Jun; 9(6):954-61. PubMed ID: 1851821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer.
    van Zandwijk N; Jassem E; Bonfrer JM; Mooi WJ; van Tinteren H
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):37-43. PubMed ID: 1329221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
    Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206
    [No Abstract]   [Full Text] [Related]  

  • 32. Serum lactate dehydrogenase predicts brain metastasis and survival in limited-stage small cell lung cancer patients treated with thoracic radiotherapy and prophylactic cranial irradiation.
    Liu J; Wu D; Shen B; Chen M; Zhou X; Zhang P; Qiu G; Ji Y; Du X; Yang Y
    Strahlenther Onkol; 2022 Dec; 198(12):1094-1104. PubMed ID: 35857072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Tc-99m sestamibi, serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy in small cell lung cancer.
    Lim SC; Park KO; Kim YC; Na KJ; Song H; Bom HS
    Cancer Biother Radiopharm; 2000 Aug; 15(4):381-6. PubMed ID: 11041023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyponatremia as prognostic factor in small cell lung cancer--a retrospective single institution analysis.
    Hermes A; Waschki B; Reck M
    Respir Med; 2012 Jun; 106(6):900-4. PubMed ID: 22405607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy.
    Bernhardt D; Aufderstrasse S; König L; Adeberg S; Bozorgmehr F; Christopoulos P; Shafie RAE; Hörner-Rieber J; Kappes J; Thomas M; Herth F; Steins M; Debus J; Rieken S
    Cancer Manag Res; 2018; 10():6563-6569. PubMed ID: 30555261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of baseline characteristics on extensive-stage SCLC patients treated with etoposide/carboplatin: A secondary analysis of a phase III study.
    Abdel-Rahman O
    Clin Respir J; 2018 Oct; 12(10):2519-2524. PubMed ID: 30073795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer.
    Liu D; Huang Y; Li L; Song J; Zhang L; Li W
    BMC Cancer; 2017 Dec; 17(1):882. PubMed ID: 29268698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia.
    Shirasawa M; Fukui T; Kusuhara S; Hiyoshi Y; Nakahara Y; Nishinarita N; Igawa S; Naoki K
    BMC Cancer; 2019 Feb; 19(1):163. PubMed ID: 30808322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
    Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
    Front Immunol; 2021; 12():724443. PubMed ID: 34777341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.